Zomig - Treatment of Acute Migraine Headache in Adolescents
Zomig - Treatment of Acute Migraine Headache in Adolescents
The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age
 12-17 years) with migraine headaches feel better. This will be done by comparing 3 different
 doses of Zomig Nasal Spray with placebo nasal spray (inactive treatment).
Inclusion Criteria:

 -  Provision of written informed consent by parent or legal guardian, and written assent
 provided by patient prior to any study specific procedures.

 -  Established diagnosis of migraine.

 -  History of a minimum of 2 migraine attacks (moderately or severely disabling)per
 month.

 Exclusion Criteria:

 -  Any medical condition that may put the patient at increased risk with exposure to
 zolmitriptan or that may interfere with the safety or efficacy assessments.

 -  A history of basilar, ophthalmoplegic, or hemiplegic migraine headache or any
 potentially serious neurological condition that is associated with headache.

 -  Have had an unacceptable adverse experience following previous use of any 5HT1B/1D
 agonist drug.